Clinical trial · Observational
Glycemic Impact on Glioblastoma Outcomes
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Logistical Issues
Summary
Brief summary (as posted)
This pilot study aims to evaluate the feasibility of close glucose monitoring and management of patients (targeting fasting and pre-meal glucose of 4-7 mmol/L) using state-of-the-art flash glucose monitoring (FGM) technology. The glycemic intervention will be personalized based on individual blood glucose levels. Although the glycemic interventions used in this study include standard medications and methods of glucose monitoring used for patients with diabetes, this pilot study will specifically evaluate the feasibility of using these approaches in patients with GBM, appreciating their additional medical, functional and social challenges.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma Multiforme | Glioblastoma | CURATED_BROADER | 0.80 |
| Hyperglycemia | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Total time spent in target glucose level
- timeFrame
- 1 week
- description
- total time spent in target range of 4-10 mmol/L based on FGM data during week 6 of radiotherapy and temozolomide therapy
Secondary outcomes (5)
- measure
- Area under the curve for glycemic exposure and variability
- timeFrame
- baseline, week 1, 2, 3, 4, 5, 6, 10-13, 3 months
- description
- Glucose levels measured using FGM vs conventional clinical measures (e.g. capillary blood glucose)
- measure
- Neurocognitive Function
- timeFrame
- Baseline
- description
- To explore the association between glycemia and neurocognitive functions patients will undergo standardized tests
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients (\> 18 years old) with a new histologically-confirmed diagnosis of glioblastoma who are planned to receive a 6-week course of concurrent radiation and temozolomide * Has evidence of random glucose of at least 7.8 mmol/L or fasting blood glucose of at least 6.1 mmol/L (meeting criteria for oral diabetic medications) * Able to provide informed consent * Able to understand and follow instructions regarding self-administered capillary glucose measurements Exclusion Criteria: * Contraindication to MRI with gadolinium * Taking anti-hyperglycemic medications at the time of study eligibility screen * Unable to participate in neurocognitive evaluation in English
References
Publications (0)
Data not yet available